| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
9,266 |
8,030 |
$2.25M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,988 |
6,400 |
$1.43M |
| G0378 |
Hospital observation service, per hour |
2,467 |
1,426 |
$498K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
7,473 |
6,725 |
$320K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,372 |
6,066 |
$280K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,794 |
2,547 |
$206K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,694 |
2,783 |
$152K |
| 80053 |
Comprehensive metabolic panel |
11,333 |
9,573 |
$123K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
15,247 |
12,365 |
$117K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,371 |
4,846 |
$115K |
| 71045 |
Radiologic examination, chest; single view |
3,650 |
3,310 |
$108K |
| 59025 |
Fetal non-stress test |
1,202 |
993 |
$95K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
121 |
104 |
$79K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,530 |
2,396 |
$68K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,594 |
2,932 |
$67K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,000 |
897 |
$64K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
229 |
214 |
$48K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,800 |
2,353 |
$42K |
| 70450 |
Computed tomography, head or brain; without contrast material |
794 |
753 |
$42K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,063 |
855 |
$40K |
| 83690 |
|
5,192 |
4,680 |
$38K |
| G0379 |
Direct admission of patient for hospital observation care |
232 |
187 |
$34K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,582 |
3,237 |
$32K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,678 |
2,396 |
$27K |
| 76801 |
|
243 |
216 |
$27K |
| 81001 |
|
7,391 |
6,630 |
$26K |
| 87081 |
|
2,116 |
2,014 |
$23K |
| 84702 |
|
1,242 |
1,065 |
$19K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
234 |
125 |
$19K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,364 |
1,675 |
$14K |
| 87040 |
|
1,909 |
995 |
$14K |
| 86140 |
|
2,121 |
1,968 |
$13K |
| 83880 |
|
982 |
899 |
$12K |
| 84484 |
|
2,133 |
1,716 |
$11K |
| 83605 |
|
1,473 |
1,140 |
$11K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,781 |
1,405 |
$10K |
| 87420 |
|
353 |
341 |
$9K |
| 84703 |
|
806 |
756 |
$9K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,795 |
1,614 |
$9K |
| 81025 |
|
672 |
639 |
$8K |
| 81003 |
|
3,120 |
2,900 |
$7K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
202 |
126 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
210 |
163 |
$7K |
| 99215 |
Prolong outpt/office vis |
46 |
24 |
$7K |
| 87581 |
|
98 |
90 |
$6K |
| 87486 |
|
98 |
90 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
574 |
544 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
939 |
764 |
$4K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,787 |
1,419 |
$4K |
| 82550 |
|
1,050 |
959 |
$4K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
92 |
86 |
$4K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
15 |
13 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,296 |
1,061 |
$3K |
| 85730 |
|
1,410 |
1,220 |
$3K |
| 85610 |
|
1,728 |
1,443 |
$3K |
| 86850 |
|
690 |
608 |
$3K |
| 87077 |
|
831 |
656 |
$3K |
| 87186 |
|
767 |
606 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,176 |
951 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,747 |
2,270 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,612 |
1,202 |
$2K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,256 |
622 |
$2K |
| 80061 |
Lipid panel |
460 |
449 |
$2K |
| J3490 |
Unclassified drugs |
612 |
423 |
$2K |
| 86900 |
|
918 |
808 |
$2K |
| 86901 |
|
917 |
807 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
381 |
360 |
$1K |
| 83735 |
|
515 |
406 |
$1K |
| 74018 |
|
31 |
28 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$1K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
28 |
27 |
$1K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
26 |
26 |
$972.30 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
14 |
14 |
$952.46 |
| 80320 |
|
59 |
54 |
$787.24 |
| CP007 |
|
29 |
17 |
$683.09 |
| J1644 |
Injection, heparin sodium, per 1000 units |
400 |
103 |
$628.38 |
| 83525 |
|
27 |
27 |
$558.29 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
20 |
13 |
$448.32 |
| 71046 |
Radiologic examination, chest; 2 views |
40 |
39 |
$372.65 |
| 82947 |
|
220 |
119 |
$321.12 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
97 |
97 |
$242.62 |
| 82805 |
|
15 |
13 |
$191.89 |
| J7510 |
Prednisolone oral, per 5 mg |
198 |
193 |
$175.96 |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
140 |
79 |
$124.69 |
| 87070 |
|
19 |
12 |
$71.32 |
| 36415 |
Collection of venous blood by venipuncture |
3,449 |
2,776 |
$58.61 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
19 |
12 |
$51.88 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
12 |
12 |
$16.32 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
238 |
214 |
$12.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
21 |
12 |
$5.28 |
| 82962 |
|
2,515 |
849 |
$4.70 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
44 |
26 |
$2.02 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
42 |
42 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
13 |
13 |
$0.00 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
50 |
41 |
$0.00 |
| 82570 |
|
14 |
14 |
$0.00 |